Nuvo Pharms Company Profile

What is the competitive landscape for NUVO PHARMS

NUVO PHARMS has twelve approved drugs.

There are four US patents protecting NUVO PHARMS drugs.

Summary for Nuvo Pharms

US Patents:	4
Tradenames:	11
Ingredients:	11
NDAs:	12

Drugs and US Patents for Nuvo Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nuvo Pharms Inc	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	207118-001	Oct 28, 2016	AA	RX	No	No
Nuvo Pharms Inc	HYDROXYZINE HYDROCHLORIDE	hydroxyzine hydrochloride	TABLET;ORAL	207121-001	Mar 29, 2017	AB	RX	No	No
Nuvo Pharms Inc	NAPROXEN	naproxen	TABLET, DELAYED RELEASE;ORAL	091432-001	Sep 19, 2011	AB	RX	No	No
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-001	Jun 15, 2007	AB	RX	Yes	No
Nuvo Pharms Inc	PENNSAID	diclofenac sodium	SOLUTION;TOPICAL	020947-001	Nov 4, 2009		DISCN	Yes	No	8,618,164

Expired US Patents for Nuvo Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-005	Mar 26, 2009	7,132,570*PED
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-004	Jun 15, 2007	7,297,346*PED
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007	7,297,346*PED
Nuvo Pharms	NUVIGIL	armodafinil	TABLET;ORAL	021875-003	Jun 15, 2007	4,927,855*PED
Nuvo Pharms	PROVIGIL	modafinil	TABLET;ORAL	020717-002	Dec 24, 1998	4,927,855*PED

Paragraph IV (Patent) Challenges for NUVO PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	100 mg and 200 mg		2009-09-11
	Topical Solution	2.0%		2014-06-03
	Tablets	50 mg, 150 mg and 250 mg		2009-07-24
	Topical Solution	1.5%		2012-07-11

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Nuvo Pharm
• Nuvo Pharms
• Nuvo Pharms Inc

Nuvo Pharms Market Analysis and Financial Projection

Here is a comprehensive analysis of Nuvo Pharmaceuticals' competitive landscape and market position:

Company Overview

Nuvo Pharmaceuticals (now rebranded as Miravo Healthcare) is a Canadian commercial healthcare company focused on pain management, allergy and dermatology products. Key points about the company:

• Headquartered in Mississauga, Ontario
• Trades on TSX under ticker MRV
• Market cap of approximately $11 million
• Annual revenue of around $69 million (2022)
• Portfolio of commercial products and manufacturing capabilities

Key Products

Nuvo's main commercial products include:

• Blexten - antihistamine for allergic rhinitis and urticaria
• Cambia - NSAID for acute migraine
• Suvexx - combination drug for acute migraine
• Pennsaid/Pennsaid 2% - topical NSAID for osteoarthritis pain
• Resultz - head lice treatment

Competitive Strengths

1. Diversified product portfolio across pain, allergy and dermatology
2. Strong presence in Canadian market
3. FDA-approved manufacturing facility in Quebec
4. Global partnerships and out-licensing deals
5. Focus on acquiring late-stage/commercial assets

Market Position

• Leader in Canadian pain and allergy markets
• Growing presence in international markets through partnerships
• Relatively small player compared to big pharma, but carved out niche in specific therapeutic areas

Key Competitors

• Major pharma companies in pain/allergy space (e.g. Pfizer, GSK)
• Other specialty pharma firms (e.g. Bausch Health, Knight Therapeutics)
• Generic manufacturers as patents expire

Strategic Insights

1. Rebranding as Miravo Healthcare signals focus on broader healthcare offerings beyond pharmaceuticals

2. Actively pursuing business development to acquire additional commercial-stage assets and diversify portfolio

3. Leveraging manufacturing capabilities to pursue contract manufacturing opportunities

4. Expanding global footprint through out-licensing deals for key products

5. Managing loss of exclusivity for mature products through lifecycle management and new formulations

6. Focusing R&D efforts on line extensions and new indications for existing products rather than novel drug discovery

7. Potential takeover target for larger specialty pharma companies looking to expand in Canada

Challenges

• Relatively small size limits ability to compete with big pharma
• Patent expirations and generic competition for key products
• High debt levels from past acquisitions
• Concentrated product portfolio with high reliance on few key brands

Outlook

Nuvo/Miravo is well-positioned in its core therapeutic areas in Canada, but faces challenges to drive significant growth. The company's strategy of acquiring commercial-stage assets and expanding globally through partnerships appears sound given its size and capabilities. Successfully executing on business development and managing the lifecycle of existing products will be key to the company's future prospects.